NEW DELHI – The Indian biotech firm Biocon Ltd. plans to buy back a stake in its research unit, Syngene, now held by GE Capital. The rapidly growing subsidiary represents more than a quarter of Biocon's revenues. The move, which will cost $35.5 million, is part of Biocon's restructuring of its R&D infrastructure, which will see some activities moved out of India.